{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T13:28:34Z","timestamp":1789392514298,"version":"build-2803163510"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Psychiatric Research"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.jpsychires.2021.05.044","type":"journal-article","created":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T12:49:41Z","timestamp":1622551781000},"page":"267-281","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["Potential therapeutic benefits of cannabinoid products in adult psychiatric disorders: A systematic review and meta-analysis of randomised controlled trials"],"prefix":"10.1016","volume":"140","author":[{"given":"Kyle A.","family":"McKee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amira","family":"Hmidan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candice E.","family":"Crocker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond W.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey H.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Crockford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Tr\u00e9panier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine J.","family":"Aitchison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip G.","family":"Tibbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpsychires.2021.05.044_bib1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ejim.2018.01.003","article-title":"The therapeutic effects of cannabis and cannabinoids: an update from the national Academies of Sciences, engineering and medicine report","volume":"49","author":"Abrams","year":"2018","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.jpsychires.2021.05.044_bib2","first-page":"e78","article-title":"Systematic review of systematic reviews for medical cannabinoids: pain, nausea and vomiting, spasticity, and harms","volume":"64","author":"Allan","year":"2018","journal-title":"Can. Fam. Physician"},{"key":"10.1016\/j.jpsychires.2021.05.044_bib3","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1001\/jamapsychiatry.2013.3947","article-title":"Nabiximols as an agonist replacement therapy during cannabis withdrawal","volume":"71","author":"Allsop","year":"2014","journal-title":"JAMA Psychiatr."},{"key":"10.1016\/j.jpsychires.2021.05.044_bib4","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/eat.22173","article-title":"Dronabinol in severe, enduring anorexia nervosa: a randomized controlled trial","volume":"47","author":"Andries","year":"2014","journal-title":"Int. J. Eat. Disord."},{"key":"10.1016\/j.jpsychires.2021.05.044_bib5","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s40519-014-0132-5","article-title":"Effect of dronabinol therapy on physical activity in anorexia nervosa: a randomised, controlled trial. Eat","volume":"20","author":"Andries","year":"2015","journal-title":"Weight Disord. - Stud. Anorexia, Bulim. Obes."},{"key":"10.1016\/j.jpsychires.2021.05.044_bib6","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2147\/TCRM.S126849","article-title":"Dronabinol oral solution in the management of anorexia and weight loss in AIDS and cancer","volume":"14","author":"Badowski","year":"2018","journal-title":"Therapeut. Clin. Risk Manag."},{"key":"10.1016\/j.jpsychires.2021.05.044_bib7","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jpsychires.2020.07.030","article-title":"Efficacy and acceptability of cannabinoids for anxiety disorders in adults: a systematic review & meta-analysis","volume":"129","author":"Bahji","year":"2020","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jpsychires.2021.05.044_bib8","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/npp.2011.6","article-title":"Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-na\u00efve social phobia patients","volume":"36","author":"Bergamaschi","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jpsychires.2021.05.044_bib9","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.drugalcdep.2015.05.013","article-title":"The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone","volume":"154","author":"Bisaga","year":"2015","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.jpsychires.2021.05.044_bib10","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S2215-0366(19)30401-8","article-title":"Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis","volume":"6","author":"Black","year":"2019","journal-title":"Lancet Psychiatr."},{"key":"10.1016\/j.jpsychires.2021.05.044_bib11","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.schres.2011.11.009","article-title":"Rimonabant for neurocognition in schizophrenia: a 16-week double blind randomized placebo controlled trial","volume":"134","author":"Boggs","year":"2012","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.jpsychires.2021.05.044_bib12","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00213-018-4885-9","article-title":"The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial","volume":"235","author":"Boggs","year":"2018","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.jpsychires.2021.05.044_bib13","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.neuro.2019.08.002","article-title":"Cannabidiol (CBD) use in psychiatric disorders: a systematic review","volume":"74","author":"Bonaccorso","year":"2019","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.jpsychires.2021.05.044_bib14","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/ajad.12963","article-title":"Cannabis and cannabinoids in mood and anxiety disorders: impact on illness onset and course, and assessment of therapeutic potential","volume":"29","author":"Botsford","year":"2020","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.jpsychires.2021.05.044_bib15","series-title":"Nabilone for the Treatment of Nausea and Vomiting or Anorexia: a Review of Clinical Effectiveness and Guidelines","author":"CADTH","year":"2019"},{"key":"10.1016\/j.jpsychires.2021.05.044_bib16","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1016\/S0140-6736(07)61721-8","article-title":"Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials","volume":"370","author":"Christensen","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.jpsychires.2021.05.044_bib17","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.euroneuro.2017.05.005","article-title":"Cannabinoids in attention-deficit\/hyperactivity disorder: a randomised-controlled trial","volume":"27","author":"Cooper","year":"2017","journal-title":"Eur. Neuropsychopharmacol"},{"key":"10.1016\/j.jpsychires.2021.05.044_bib18","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1177\/0269881110379283","article-title":"Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report","volume":"25","author":"Crippa","year":"2011","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2021.05.044_bib19","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/cpt.102","article-title":"Cannabis and the maturing brain, role in psychosis","volume":"97","author":"Crocker","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jpsychires.2021.05.044_bib20","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.biopsych.2004.12.006","article-title":"Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction","volume":"57","author":"D'Souza","year":"2005","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.jpsychires.2021.05.044_bib21","article-title":"The method quality of cross-over studies involved in Cochrane systematic reviews","volume":"10","author":"Ding","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.jpsychires.2021.05.044_bib22","doi-asserted-by":"crossref","first-page":"377S","DOI":"10.1002\/j.1552-4604.1981.tb02617.x","article-title":"The efficacy and safety of nabilone (a synthetic cannabinoid) in the treatment of anxiety","volume":"21","author":"Fabre","year":"1981","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.jpsychires.2021.05.044_bib23","doi-asserted-by":"crossref","first-page":"l1141","DOI":"10.1136\/bmj.l1141","article-title":"Medicinal use of cannabis based products and cannabinoids","volume":"365","author":"Freeman","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.jpsychires.2021.05.044_bib24","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1001\/jamapsychiatry.2018.4500","article-title":"Association of cannabis use in adolescence and risk of depression, anxiety, and suicidality in young adulthood","volume":"76","author":"Gobbi","year":"2019","journal-title":"JAMA Psychiatr."},{"key":"10.1016\/j.jpsychires.2021.05.044_bib25","series-title":"Drug and health product review and approval","author":"Government of Canada","year":"2019"},{"key":"10.1016\/j.jpsychires.2021.05.044_bib26","series-title":"Marinol (dronabinol): cancelled post market","author":"Government of Canada","year":"2019"},{"key":"10.1016\/j.jpsychires.2021.05.044_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fpsyt.2021.620073","article-title":"Prospects for the use of cannabinoids in psychiatric disorders","volume":"12","author":"Graczyk","year":"2021","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.jpsychires.2021.05.044_bib28","first-page":"29","article-title":"A revised tool for assessing risk of bias in randomized trials","volume":"10","author":"Higgins","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jpsychires.2021.05.044_bib29","series-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 6.0","year":"2019"},{"key":"10.1016\/j.jpsychires.2021.05.044_bib30","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/ajad.12622","article-title":"Nabilone pharmacotherapy for cannabis dependence: a randomized, controlled pilot study","volume":"26","author":"Hill","year":"2017","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.jpsychires.2021.05.044_bib31","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/S2215-0366(20)30074-2","article-title":"Psychiatric symptoms caused by cannabis constituents: a systematic review and meta-analysis","volume":"7","author":"Hindley","year":"2020","journal-title":"Lancet Psychiatr."},{"key":"10.1016\/j.jpsychires.2021.05.044_bib32","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00406-019-00984-4","article-title":"How effective and safe is medical cannabis as a treatment of mental disorders? A systematic review","volume":"269","author":"Hoch","year":"2019","journal-title":"Eur. Arch. Psychiatr. Clin. Neurosci."},{"key":"10.1016\/j.jpsychires.2021.05.044_bib33","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1176\/appi.ajp.2019.18101191","article-title":"Cannabidiol for the reduction of cue-induced craving and anxiety in drug-abstinent individuals with heroin use disorder: a double-blind randomized placebo-controlled trial","volume":"176","author":"Hurd","year":"2019","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.jpsychires.2021.05.044_bib34","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.psyneuen.2014.11.002","article-title":"The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: a preliminary randomized, double-blind, placebo-controlled cross-over design study","volume":"51","author":"Jetly","year":"2015","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.jpsychires.2021.05.044_bib35","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/da.23032","article-title":"Acute effects of cannabinoids on symptoms of obsessive\u2010compulsive disorder: a human laboratory study","volume":"37","author":"Kayser","year":"2020","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.jpsychires.2021.05.044_bib36","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1001\/archpsyc.62.6.593","article-title":"Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the national comorbidity survey replication","volume":"62","author":"Kessler","year":"2005","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.jpsychires.2021.05.044_bib37","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/15622975.2017.1285049","article-title":"Is there a role for cannabidiol in psychiatry?","volume":"20","author":"Khoury","year":"2019","journal-title":"World J. Biol. Psychiatr."},{"key":"10.1016\/j.jpsychires.2021.05.044_bib38","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.drugalcdep.2010.12.010","article-title":"Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial","volume":"116","author":"Levin","year":"2011","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.jpsychires.2021.05.044_bib39","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1038\/tp.2012.15","article-title":"Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia","volume":"2","author":"Leweke","year":"2012","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.jpsychires.2021.05.044_bib40","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1001\/jamainternmed.2019.1993","article-title":"Nabiximols for the treatment of cannabis dependence A randomized clinical trial","volume":"179","author":"Lintzeris","year":"2019","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.jpsychires.2021.05.044_bib41","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.drugalcdep.2016.05.002","article-title":"Opioid withdrawal suppression efficacy of oral dronabinol in opioid dependent humans","volume":"164","author":"Lofwall","year":"2016","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.jpsychires.2021.05.044_bib42","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.drugalcdep.2015.01.046","article-title":"Effect of oral THC pretreatment on marijuana cue-induced responses in cannabis dependent volunteers","volume":"149","author":"Lundahl","year":"2015","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.jpsychires.2021.05.044_bib43","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/YCO.0b013e3283477a09","article-title":"Age of onset and timing of treatment for mental and substance use disorders: implications for preventive intervention strategies and models of care","volume":"24","author":"McGorry","year":"2011","journal-title":"Curr. Opin. Psychiatr."},{"key":"10.1016\/j.jpsychires.2021.05.044_bib44","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1176\/appi.ajp.2017.17030325","article-title":"Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial","volume":"175","author":"McGuire","year":"2018","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.jpsychires.2021.05.044_bib45","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1176\/appi.ajp.161.6.975","article-title":"Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder","volume":"161","author":"Meltzer","year":"2004","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.jpsychires.2021.05.044_bib46","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting Items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med."},{"key":"10.1016\/j.jpsychires.2021.05.044_bib47","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1016\/j.addbeh.2013.03.011","article-title":"Cannabidiol reduces cigarette consumption in tobacco smokers: preliminary findings","volume":"38","author":"Morgan","year":"2013","journal-title":"Addict. Behav."},{"key":"10.1016\/j.jpsychires.2021.05.044_bib48","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1055\/s-2002-25028","article-title":"Treatment of Tourette's syndrome with \u0394 9 -tetrahydrocannabinol (THC): a randomized crossover trial","volume":"35","author":"M\u00fcller-Vahl","year":"2002","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.jpsychires.2021.05.044_bib49","doi-asserted-by":"crossref","first-page":"459","DOI":"10.4088\/JCP.v64n0417","article-title":"Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in tourette syndrome: a 6-week randomized trial","volume":"64","author":"Muller-Vahl","year":"2003","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.jpsychires.2021.05.044_bib50","series-title":"StatPearls [Internet]","author":"O'Donnell","year":"2020"},{"key":"10.1016\/j.jpsychires.2021.05.044_bib51","doi-asserted-by":"crossref","first-page":"393","DOI":"10.14740\/jocmr4159","article-title":"The impact of cannabidiol on psychiatric and medical conditions","volume":"12","author":"Oberbarnscheidt","year":"2020","journal-title":"J. Clin. Med. Res."},{"key":"10.1016\/j.jpsychires.2021.05.044_bib52","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1111\/j.1464-410X.2009.08556.x","article-title":"Levels of evidence","volume":"103","author":"Phillips","year":"2009","journal-title":"BJU Int."},{"key":"10.1016\/j.jpsychires.2021.05.044_bib53","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1177\/0706743719895195","article-title":"Cannabidiol as a treatment for mood disorders: a systematic review","volume":"65","author":"Pinto","year":"2020","journal-title":"Can. J. Psychiatr."},{"key":"10.1016\/j.jpsychires.2021.05.044_bib54","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/adb.12508","article-title":"Pooled analysis of three randomized, double-blind, placebo controlled trials with rimonabant for smoking cessation","volume":"23","author":"Robinson","year":"2018","journal-title":"Addiction Biol."},{"key":"10.1016\/j.jpsychires.2021.05.044_bib55","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1037\/a0030992","article-title":"Reliability of the Timeline Followback for cocaine, cannabis, and cigarette use","volume":"28","author":"Robinson","year":"2014","journal-title":"Psychol. Addict. Behav."},{"key":"10.1016\/j.jpsychires.2021.05.044_bib56","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12888-019-2409-8","article-title":"Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review","volume":"20","author":"Sarris","year":"2020","journal-title":"BMC Psychiatr."},{"key":"10.1016\/j.jpsychires.2021.05.044_bib57","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.drugalcdep.2018.02.022","article-title":"The effect of high-dose dronabinol (oral THC) maintenance on cannabis self-administration","volume":"187","author":"Schlienz","year":"2018","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.jpsychires.2021.05.044_bib58","doi-asserted-by":"crossref","DOI":"10.1002\/hup.1196","article-title":"A randomized, double-blind, placebo-controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use","volume":"26","author":"Schoedel","year":"2011","journal-title":"Hum. Psychopharmacol. Clin. Exp."},{"key":"10.1016\/j.jpsychires.2021.05.044_bib59","series-title":"Handbook for Grading the Quality of Evidence and the Strength of Recommendations Using the GRADE Approach. GRADE Working Group","year":"2013"},{"key":"10.1016\/j.jpsychires.2021.05.044_bib60","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/ptr.5975","article-title":"Cannabinoids for nausea and vomiting related to chemotherapy: overview of systematic reviews","volume":"32","author":"Schussel","year":"2018","journal-title":"Phyther. Res."},{"key":"10.1016\/j.jpsychires.2021.05.044_bib61","series-title":"The Health Effects of Cannabis and Cannabinoids: the Current State of Evidence and Recommendations for Research","year":"2017"},{"key":"10.1016\/j.jpsychires.2021.05.044_bib62","article-title":"Are there therapeutic benefits of cannabinoid products in adult mental illness?","author":"Tibbo","year":"2020","journal-title":"Can. J. Psychiatr."},{"key":"10.1016\/j.jpsychires.2021.05.044_bib63","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.drugalcdep.2016.02.020","article-title":"Effects of fixed or self-titrated dosages of Sativex on cannabis withdrawal and cravings","volume":"161","author":"Trigo","year":"2016","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.jpsychires.2021.05.044_bib64","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0190768","article-title":"Nabiximols combined with motivational enhancement\/cognitive behavioral therapy for the treatment of cannabis dependence: a pilot randomized clinical trial","volume":"13","author":"Trigo","year":"2018","journal-title":"PloS One"},{"key":"10.1016\/j.jpsychires.2021.05.044_bib65","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.drugalcdep.2012.08.001","article-title":"The dose effects of short-term dronabinol (oral THC) maintenance in daily cannabis users","volume":"128","author":"Vandrey","year":"2013","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.jpsychires.2021.05.044_bib66","unstructured":"Veritas Health Innovation, n.d. Covidence Systematic Review Software."},{"issue":"24","key":"10.1016\/j.jpsychires.2021.05.044_bib67","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1001\/jama.2015.6358","article-title":"Cannabinoids for Medical Use: A Systematic Review and Meta-analysis","volume":"313","author":"Whiting","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.jpsychires.2021.05.044_bib68","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.4088\/JCP.15r10036","article-title":"A systematic review of the evidence for medical marijuana in psychiatric indications","volume":"77","author":"Wilkinson","year":"2016","journal-title":"J. Clin. Psychiatr."}],"container-title":["Journal of Psychiatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395621003149?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395621003149?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T11:22:19Z","timestamp":1758367339000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022395621003149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":68,"alternative-id":["S0022395621003149"],"URL":"https:\/\/doi.org\/10.1016\/j.jpsychires.2021.05.044","relation":{},"ISSN":["0022-3956"],"issn-type":[{"value":"0022-3956","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potential therapeutic benefits of cannabinoid products in adult psychiatric disorders: A systematic review and meta-analysis of randomised controlled trials","name":"articletitle","label":"Article Title"},{"value":"Journal of Psychiatric Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpsychires.2021.05.044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2021 Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}